Oxygenta Pharmaceutical Ltd - Stock Valuation and Financial Performance

BSE: 524636 | NSE: | Pharmaceuticals & Drugs | Small Cap

Oxygenta Pharma Share Price

90.14 -1.83 -1.99%
as on 20-Dec'24 16:59

DeciZen - make an informed investing decision on Oxygenta Pharma

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Oxygenta Pharmaceutical stock performance -

mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
333.4 Cr.
52-wk low:
26
52-wk high:
108.6

Is Oxygenta Pharmaceutical Ltd an attractive stock to invest in?

1. Is Oxygenta Pharmaceutical Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Oxygenta Pharmaceutical Ltd is a below average quality company.

2. Is Oxygenta Pharmaceutical Ltd undervalued or overvalued?

The key valuation ratios of Oxygenta Pharmaceutical Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Oxygenta Pharmaceutical Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Oxygenta Pharmaceutical Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Oxygenta Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Oxygenta Pharmaceutical Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % 0%0%0%0%0%0%0%3.2%-50.3%-41.7%-
Value Creation
Index
NANANANANANANANANANA-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 6.212.48.212.920.513.75260.53139.646
Sales YoY Gr.-99.2%-34.4%57.9%59.4%-33.1%279.2%16.3%-48.8%27.9%-
Adj EPS -6-5.4-5.7-4.4-3.2-8.42.9-0-7.8-1.10
YoY Gr.-NANANANANANA-101.1%NANA-
BVPS (₹) -15.8-21.1-26.8-31.3-34.5-40.1-37.3-24.4-32.5-6.2-5.3
Adj Net
Profit
-6.1-5.5-5.8-4.5-3.3-8.62.90-11.1-3.50
Cash Flow from Ops. -4.30.90.51.3-7.8-2.6-1.6-1.7-1.6-13.1-
Debt/CF from Ops. -3.420.63714.9-2.9-10.4-29.5-31-41.6-4.4-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 22.8%14.1%-8.7%27.9%
Adj EPS NANA-171.5%NA
BVPSNANANANA
Share Price 26.8% 65.3% 47.9% 185.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
48.329.223.715.39.722.5-7.40.127.410.6-0.2
Op. Profit
Mgn %
-66.1-33.5-59.4-31.1-10-57.47.42.4-23-24.4-15.7
Net Profit
Mgn %
-98-44.3-71.2-35.2-15.9-62.55.6-0.1-35.7-8.90.1
Debt to
Equity
-0.9-0.8-0.7-0.6-0.6-0.7-1.3-1.5-1.5-2.8-
Working Cap
Days
2561942901511222168282217235103
Cash Conv.
Cycle
-264-247-229-154-75-14-1105226-37

Recent Performance Summary

Sales growth is good in last 4 quarters at 34.12%

Return on Equity is Poor

Sales growth has been subdued in last 3 years -8.67%

Net Profit has been subdued in last 3 years -171.52%

Latest Financials - Oxygenta Pharmaceutical Ltd.

Standalone Consolidated
TTM EPS (₹) 0 -
TTM Sales (₹ Cr.) 46.3 -
BVPS (₹.) -5.3 -
Reserves (₹ Cr.) -56 -
P/BV -17.14 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 26.01 / 108.64
All Time Low / High (₹) 0.10 / 108.64
Market Cap (₹ Cr.) 333
Equity (₹ Cr.) 37
Face Value (₹) 10
Industry PE 44.3

Management X-Ray of Oxygenta Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Oxygenta Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales612813211452613140
Operating Expenses 10171317232248593849
Manufacturing Costs3333226977
Material Costs28610161637472434
Employee Cost 3333324166
Other Costs 2221112222
Operating Profit -4-4-5-4-2-841-7-10
Operating Profit Margin (%) -66.1%-33.5%-59.4%-31.1%-10.0%-57.4%7.4%2.4%-23.0%-24.5%
Other Income 0011000000
Interest 0111112112
Depreciation 3111111223
Exceptional Items 00000421-10
Profit Before Tax -7-6-6-4-3-630-11-14
Tax -100000000-10
Profit After Tax -6-5-6-5-3-63-1-12-3
PAT Margin (%) -98.0%-44.3%-71.2%-35.2%-15.9%-42.2%5.6%-1.0%-37.3%-8.8%
Adjusted EPS (₹)-6.0-5.4-5.7-4.4-3.2-5.72.9-0.4-8.2-1.0
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund -16-22-27-32-35-41-38-35-46-21
Share Capital 10101010101010141433
Reserves -26-32-38-42-45-51-48-49-60-54
Minority Interest0000000000
Debt14171818212648526756
Long Term Debt14171818212545516249
Short Term Debt0000003157
Trade Payables1115911981462423
Others Liabilities 810192026261079-4
Total Liabilities 18201917211934315454

Fixed Assets

Gross Block21232324252531364651
Accumulated Depreciation9101112131415161921
Net Fixed Assets12131212121116202829
CWIP 0000001000
Investments 0000000000
Inventories1122541271214
Trade Receivables11101022107
Cash Equivalents 0000000000
Others Assets5433323244
Total Assets 18201917211934315454

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity -4111-8-3-2-2-2-13
PBT -7-6-6-4-3-630-11-14
Adjustment 3112223344
Changes in Working Capital -0554-61-8-46-3
Tax Paid 0000000000
Cash Flow From Investing Activity 1-2-10-10-7-5-10-4
Capex -2-2-10-1-1-7-500
Net Investments 0000000000
Others 30000000-10-4
Cash Flow From Financing Activity 310-183961117
Net Proceeds from Shares 00000004029
Net Proceeds from Borrowing 42109410313-11
Interest Paid 0-1-1-1-1-1-2-1-1-2
Dividend Paid 0000000000
Others 0000000001
Net Cash Flow 0000000000
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
ROCE (%)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Asset Turnover Ratio0.340.660.420.711.080.691.981.860.730.73
PAT to CFO Conversion(x)N/AN/AN/AN/AN/AN/A-0.67N/AN/AN/A
Working Capital Days
Receivable Days443153199127106981
Inventory Days16216349611285758112117
Payable Days1,62258479036822420010978230254

Oxygenta Pharmaceutical Ltd Stock News

Oxygenta Pharmaceutical Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Oxygenta Pharma on 20-Dec-2024 16:59 is ₹90.14.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of Oxygenta Pharma stood at ₹333.4.
The latest P/E ratio of Oxygenta Pharma as of 20-Dec-2024 16:59 is 0.00.
The latest P/B ratio of Oxygenta Pharma as of 20-Dec-2024 16:59 is -17.14.
The 52-week high of Oxygenta Pharma is ₹108.6 and the 52-week low is ₹26.01.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Oxygenta Pharma is ₹46.33 ( Cr.) .

About Oxygenta Pharmaceutical Ltd

SS Organics was incorporated in 1990, is a pharmaceutical company involved in the manufacture and marketing of bulk drugs and intermediates.

A wide range of new generation quinolones, antiasthmatic, antiulcerant, and anti-inflammatory drugs are manufactured. The product range also includes omeprazole, rabeprazole sodium, lansoprazole, esomeprazole magnesium trihydrate, non-pariel seeds, pantoprazole pellets, diclofenac sodium pellets, gabapentior, mooxafloxacin, ramipril, atorvastatin, and voriconazole.

Designed and built as per US FDA standards for production of bulk drugs and custom synthesis of intermediates, the plant located in the Medak district of Andhra Pradesh has an installed capacity 320 TPA. Major export destinations include Europe, USA, South America, and Asia Pacific Region. It reaches the America markets through its subsidiary based in Maryland, USA.

The registered office is at Survey No 252/1, Aroor Village, Sadasivapet Mandal, Medak, Andhra Pradesh.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.